EyePoint, Inc.

EyePoint, Inc. is a biotechnology company focused on developing and commercializing therapeutics for serious retinal diseases. Its pipeline leverages the proprietary Durasert E technology, a bioerodible system for sustained intraocular drug delivery. The lead product candidate is DURAVYU, an investigational treatment combining vorolanib (a selective tyrosine kinase inhibitor) with Durasert E for vascular endothelial growth factor mediated retinal diseases. DURAVYU is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Another pipeline program is EYP-2301, a TIE-2 agonist formulated in Durasert E, currently in pre-clinical development to potentially improve outcomes in serious retinal diseases.

EyePoint, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol EYPT. The company operates in the United States and its financials are reported in US Dollars (USD). As a Nasdaq-listed company, it is subject to US securities regulations and reporting standards.

EyePoint, Inc. operates in the Healthcare sector and specifically within the Biotechnology industry. As a biotechnology company, it focuses on research, development, and commercialization of therapies for medical conditions, particularly serious retinal diseases. The company's work involves advanced drug delivery technologies and clinical-stage product candidates targeting eye diseases like wet age-related macular degeneration and diabetic macular edema.

EyePoint, Inc. is headquartered in Watertown, Massachusetts, United States. The company was founded in 2000 and was formerly known as EyePoint Pharmaceuticals, Inc. before rebranding to EyePoint, Inc. in December 2025. The company primarily serves the US market, focusing on developing treatments for retinal diseases.

The core technology of EyePoint, Inc. is its proprietary Durasert E system, a bioerodible platform designed for sustained intraocular drug delivery. This technology allows for controlled release of therapeutics directly into the eye over an extended period, potentially reducing the need for frequent injections. The lead candidate DURAVYU uses Durasert E to deliver vorolanib, a tyrosine kinase inhibitor, for retinal diseases. Another early-stage program, EYP-2301, employs Durasert E to deliver a TIE-2 agonist. This technology is central to the company's strategy for treating chronic retinal conditions.